Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON 2: Alectinib + Chemotherapy in Resectable ALK+ NSCLC
NCT06624059Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2024
- Primary completion
- Jul 2026
- Countries
- 6
01
Overview
A Phase 3 trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Nov 2024; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06624059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624059.